Nexavar^®

Nexavar^® is a prescription, anticancer medicine approved by the U.S. FDA in 2005 for treatment of advanced kidney cancer. Also called renal cell carcinoma (RCC), advanced kidney cancer is the most commonly diagnosed form of kidney cancer.

Part of a new class of cancer medications called targeted therapies, Nexavar^® is a multikinase inhibitor that targets a number of serine/threonine and receptor tyrosine kinases, interfering with processes that supply cancer tumors with blood and aid in their growth.

Nexavar^® is an oral medication, usually taken as two 200 mg tablets twice a day.

At Cancer Treatment Centers of America (CTCA), our cancer doctors will work together with you so you can make an informed decision about whether or not to incorporate Nexavar^® into your renal cell carcinoma treatment. Our whole-patient approach also offers complementary and alternative medicines to help improve quality of life and increase the effectiveness of anticancer medications such as Nexavar^®.

Chat now with an Oncology Information Specialist to learn more about our integrative approach to advanced kidney cancer treatment.

Advanced kidney cancer treatment with Nexavar^® affects each patient differently. Nexavar^® has been associated with the following side effects, which you or a loved one may or may not experience as a result of treatment:

• Serious birth defects or death of an unborn baby
• Hand-foot skin reaction (redness, pain, swelling, or blisters on the palms of your hands or soles of your feet)
• High blood pressure
• Heart problems
• Increased risk of bleeding
• Itchy or patchy skin
• Numbness or tingling in the hands or feet
• Diarrhea
• Nausea and/or vomiting
• Loss of appetite
• Hair thinning or patchy hair loss
• Mouth sores
• Fatigue/weakness

Please note, the side effects listed above should not be considered a comprehensive list of side effects. Nexavar^® treatment may also entail additional, less common side effects. Pregnant women should not take Nexavar^®. Additionally, women should not get pregnant during treatment with Nexavar^® and for at least two weeks after treatment stops.

Your integrative care team at Cancer Treatment Centers of America (CTCA) will work with you to educate you about possible side effects of Nexavar^®, and also to ensure your comfort throughout your kidney cancer treatment. If you experience any symptom that bothers you or does not go away, it is important to let the CTCA team know.

Nexavar^® is approved by the U.S. FDA for treatment of advanced kidney cancer, also known as advanced renal cell carcinoma (RCC).

A multikinase inhibitor, Nexavar^® works to stop kidney cancer tumors from spreading by reducing the blood supply to the tumor, as well as interfering with the ability of kidney cancer cells to reproduce.

To learn more about how integrative treatments at Cancer Treatment Centers of America (CTCA) work to fight advanced kidney cancer on as many fronts as possible, chat now with an Oncology Information Specialist.